Skip to Main Content

Paper Details

In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Kidney Int
2
2022
Author NameAffiliation
Jochen HechtBarcelona Institute of Science and Technology, Universitat Pompeu Fabra
  • 1 - 1

Datasets

Release 1.2